NVO and VKTX face rising competition and setbacks as investors weigh scale, pipelines and execution risks in the crowded ...

Novo Nordisk A/S Q3 costs, Q4 savings, and oral Wegovy launch drive EPS upside. Click for this NVO stock update and earnings preview.

Novo Nordisk AS was sued in federal court Friday with allegations that it monopolized the blockbuster weight loss medication Victoza through an illegal deal with a competitor to delay the generic, ...

Recent Returns Put Long Term Performance in Context Novo Nordisk (NVO) has drawn attention after recent share price moves, ...

DCGI approval to Sun Pharma comes amid an ongoing patent dispute with Novo Nordisk in the Delhi High Court. The case relates ...

Sun Pharma plans to launch by March and sell in five doses similar to the innovator Novo Nordisk’s drug Wegovy.

Novo Nordisk A/S (NOVO:CA) 44th Annual J.P. Morgan Healthcare Conference January 13, 2026 12:45 PM ESTCompany ParticipantsMaziar Doustdar - President, ...

Cash-pay platform brings transparent pricing and direct provider access to first and only oral GLP-1 weight loss medication ...

Better regulation and enforcement urged before launch of oral treatments, which criminals are likely to try to exploit ...

Add Yahoo as a preferred source to see more of our stories on Google. FILE PHOTO: Pens for the diabetes drug Ozempic sit on a production line to be packaged at the Danish drugmaker Novo Nordisk's site ...

Despite ushering in the current GLP-1 era, Novo Nordisk has fallen behind its chief rival Eli Lilly, which has exceeded the Danish pharma in terms of sales.

Besides Sun Pharma, a growing roster of Indian drugmakers is lining up cheaper generic versions of semaglutide ahead of the ...